March 3 (Reuters) – Hims & Hers Health’s pharmacy partner, Strive Pharmacy, plans to resume sales of its compounded weight‑loss pill through other healthcare providers after halting distribution following U.S. regulatory pushback, Endpoints News reported on Tuesday.
Arizona-based Strive has not decided on a timeline yet but will wait to see how “everything settles out before we reintroduce it,” the report said, citing an interview with the management of the compounding pharmacy behind Hims’ pill.
Last month, Hims announced plans to offer a compounded oral semaglutide pill for $49, a version of Novo Nordisk’s new Wegovy pill launched just a month earlier.
The risky move was quick to earn backlash from Novo and the U.S. Food and Drug Administration, which referred the company to the Department of Justice and threatened to restrict the ingredients that pharmacies mix to make their compounded versions.
Novo Nordisk’s Denmark-listed shares were down nearly 2%, while rival Eli Lilly was down 1.7% after the report on Tuesday.
Strive and Novo did not immediately respond to Reuters’ requests for comment.
(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
